Blue Whale Capital LLP Buys 16,500 Shares of Danaher Corporation $DHR

Key Points

• Blue Whale Capital LLP has increased its stake in Danaher Corporation by 5.0%, now owning 346,246 shares valued at approximately $70.98 million, which represents 5.7% of its total holdings.
• Analysts have issued varying price targets for Danaher, with Barclays setting a target of $225.00 while Scotiabank has raised its target to $275.00; the stock currently has an average rating of "Moderate Buy."
• In its latest quarterly results, Danaher reported earnings per share of $1.80, surpassing analyst expectations, and expects to achieve earnings per share of 7.700-7.800 for the fiscal year 2025.

Blue Whale Capital LLP increased its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 5.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 346,246 shares of the conglomerate's stock after buying an additional 16,500 shares during the period. Danaher comprises approximately 5.7% of Blue Whale Capital LLP's holdings, making the stock its 7th biggest position. Blue Whale Capital LLP's holdings in Danaher were worth $70,980,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. GHP Investment Advisors Inc. boosted its stake in Danaher by 396.0% during the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after purchasing an additional 99 shares during the period. Heck Capital Advisors LLC acquired a new position in Danaher during the 4th quarter valued at about $27,000. Sierra Ocean LLC boosted its stake in Danaher by 116.9% during the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock valued at $29,000 after purchasing an additional 76 shares during the period. Smallwood Wealth Investment Management LLC acquired a new position in Danaher during the 1st quarter valued at about $31,000. Finally, Dunhill Financial LLC boosted its stake in Danaher by 68.4% during the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock valued at $34,000 after purchasing an additional 67 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Price Performance

Shares of NYSE:DHR traded down $1.26 during trading on Tuesday, reaching $206.47. The company had a trading volume of 3,653,927 shares, compared to its average volume of 4,205,962. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The firm's fifty day moving average is $200.81 and its 200 day moving average is $199.38. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.90. The firm has a market capitalization of $147.84 billion, a PE ratio of 43.93, a price-to-earnings-growth ratio of 2.96 and a beta of 0.73.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. The firm had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm's revenue for the quarter was up 3.4% compared to the same quarter last year. During the same period last year, the firm posted $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on DHR shares. Barclays reissued an "overweight" rating and set a $225.00 target price (up from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. UBS Group reduced their target price on shares of Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a research note on Wednesday, July 23rd. Robert W. Baird boosted their target price on shares of Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research note on Friday, July 18th. Scotiabank raised shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price for the company in a research note on Friday, July 11th. Finally, Wells Fargo & Company reduced their price target on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 23rd. Seventeen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat, Danaher currently has a consensus rating of "Moderate Buy" and a consensus target price of $247.61.

Insider Buying and Selling at Danaher

In related news, Director Teri List sold 2,778 shares of Danaher stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director directly owned 20,751 shares in the company, valued at $4,379,706.06. The trade was a 11.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 11.20% of the stock is currently owned by corporate insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.